Table 7.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1996 to 2005

Recipients with Pancreas After Kidney (PAK) Transplants

  Year of Transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 113 130 156 220 304 305 375 344 420 343
Tx with Antirejection Treatments 37 41 44 57 65 45 43 61 59 47
Antibodies Any in Category 75.7% 61.0% 59.1% 75.4% 53.8% 60.0% 48.8% 65.6% 59.3% 74.5%
Atgam/NRATG/NRATS 13.5% 17.1% 9.1% 1.8% 1.5% 2.2% 0.0% 3.3% 0.0% 0.0%
OKT3 67.6% 51.2% 45.5% 63.2% 35.4% 26.7% 25.6% 13.1% 15.3% 12.8%
Thymoglobulin 0.0% 0.0% 2.3% 22.8% 21.5% 33.3% 30.2% 45.9% 44.1% 61.7%
Zenapax 0.0% 0.0% 2.3% 1.8% 1.5% 2.2% 2.3% 6.6% 0.0% 4.3%
Simulect 0.0% 0.0% 0.0% 0.0% 4.6% 4.4% 0.0% 4.9% 0.0% 2.1%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 27.9% 8.5% 6.4%
Corticosteroids Any in Category 64.9% 78.0% 70.5% 84.2% 87.7% 86.7% 90.7% 68.9% 79.7% 61.7%
Steroids 64.9% 78.0% 70.5% 84.2% 87.7% 86.7% 90.7% 68.9% 79.7% 61.7%
Antimetabolites Any in Category 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 1, 2007.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.